172 related articles for article (PubMed ID: 29055158)
1. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
Nasir A; Bissonnette R; Maari C; DuBois J; Pene Dumitrescu T; Haddad J; Yamaguchi Y; Dalessandro M
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):145-151. PubMed ID: 29055158
[TBL] [Abstract][Full Text] [Related]
2. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Feldman G; Walker RR; Brooks J; Mehta R; Crater G
Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
[TBL] [Abstract][Full Text] [Related]
3. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
[TBL] [Abstract][Full Text] [Related]
4. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
7. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
8. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
Manickam R; Asija A; Aronow WS
Expert Opin Drug Saf; 2014 Nov; 13(11):1555-61. PubMed ID: 25294427
[TBL] [Abstract][Full Text] [Related]
9. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
[TBL] [Abstract][Full Text] [Related]
10. Pharmacometrics-guided drug development of antihyperhidrosis agents.
Mehrotra S; Schmith VD; Dumitrescu TP; Gobburu J
J Clin Pharmacol; 2015 Nov; 55(11):1256-67. PubMed ID: 25939678
[TBL] [Abstract][Full Text] [Related]
11. A Novel Method for Studying the Pharmacokinetics of [(14) C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects.
Pene Dumitrescu T; Santos LL; Hughes SC; Pereira AI; Young GC; Hussey E; Charlton P; Baptiste-Brown S; Stuart JS; Vincent V; van Marle SP; Schmith VD
Clin Transl Sci; 2016 Aug; 9(4):183-91. PubMed ID: 27304394
[TBL] [Abstract][Full Text] [Related]
12. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
Mehta R; Hardes K; Kelleher D; Preece A; Tombs L; Brealey N
Clin Ther; 2014 Jul; 36(7):1016-1027.e2. PubMed ID: 24947493
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
[TBL] [Abstract][Full Text] [Related]
14. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Mehta R; Green M; Patel B; Wagg J
J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):153-64. PubMed ID: 26739997
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
16. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Artzi O; Loizides C; Zur E; Sprecher E
Acta Derm Venereol; 2017 Oct; 97(9):1120-1124. PubMed ID: 28654131
[TBL] [Abstract][Full Text] [Related]
17. Long-term (52 weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease.
Yamagata E; Soutome T; Hashimoto K; Mihara K; Tohda Y
Curr Med Res Opin; 2016 May; 32(5):967-73. PubMed ID: 26782971
[TBL] [Abstract][Full Text] [Related]
18. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
Donohue JF; Kalberg C; Shah P; Beerahee M; Mehta R; Gunawan R; Church A
J Clin Pharmacol; 2014 Nov; 54(11):1214-20. PubMed ID: 24895108
[TBL] [Abstract][Full Text] [Related]
19. Topical Botulinum Toxin Type A Liposomal Cream for Primary Axillary Hyperhidrosis: A Double-Blind, Randomized, Split-Site, Vehicle-Controlled Study.
Lueangarun S; Sermsilp C; Tempark T
Dermatol Surg; 2018 Aug; 44(8):1094-1101. PubMed ID: 29659406
[TBL] [Abstract][Full Text] [Related]
20. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
